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may be associated with low adherence.
Methods:	 This	 cross-	sectional	 observational	 study	 compared	 illness	 beliefs,	 treat-
ment	beliefs,	and	treatment	satisfaction	of	patients	with	TTR	>75%	and	TTR	<50%	




>75%	patients	had	been	 taking	warfarin	on	average	over	2	years	 longer	 than	TTR	
<50%	patients	(P < .001).	Statistically	significant	differences	in	beliefs	were	found	in	
all	 subscales	 other	 than	 in	 treatment	 control,	 general	 harm,	 and	 general	 overuse.	
Cluster	analysis	determined	there	were	4	distinct	clusters	of	beliefs	among	patients.	
Multivariate	binary	logistic	regression	found	VTE	patients	were	least	likely	to	have	






K E Y W O R D S
adherence,	anticoagulation,	atrial	fibrillation,	illness	belief,	medication	beliefs,	quality	of	life,	
time	in	therapeutic	range,	venous	thromboembolism,	vitamin-K	antagonists,	warfarin
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1  | INTRODUC TION
Guidelines	 recommend	 lifelong	 anticoagulation	 in	 atrial	 fibrillation	
(AF)	in	the	presence	of	stroke	risk	factors,1,2 as well as in the second-
ary	prevention	of	venous	thromboembolism	(VTE).3,4	Nonadherence	
to	 anticoagulation	 therapy	 is	 known	 to	 impact	 treatment	 out-
comes,5,6	where	adherence	is	defined	as	the	extent	to	which	a	pa-
tient	takes	their	medication	as	prescribed.7
Time	 in	 therapeutic	 range	 (TTR)	 using	 the	 Rosendaal	 method	
indicates	international	normalized	ratio	(INR)	control,	where	a	TTR	
>65%	 is	 considered	 good	 and	 indicative	 of	 treatment	 adherence	
to	 vitamin-	K	 antagonists	 (VKAs).2,8,9	 Low	TTR	has	been	 shown	 to	
be	 associated	 with	 both	 poor	 adherence	 and	 worse	 clinical	 out-
comes.10,11	Long-	term	VKA	therapy	presents	unique	challenges	re-






ence can be objectively assessed.
Nonadherence	is	prevalent	in	chronic	disease	where	up	to	50%	
of	 patients	 are	 reportedly	 nonadherent.15,16	 Unintentional	 nonad-











herence	 to	VKAs,22	 there	 is	a	paucity	of	 research	determining	 the	









This	 cross-	sectional	 observational	 study	 was	 conducted	 in	 the	
outpatient	 setting	 across	 the	 two	 anticoagulation	 clinics	 of	 King’s	
College	Hospital	NHS	Foundation	Trust	in	South	East	London.	The	
Denmark	Hill	 (DH)	 site	 is	 a	 tertiary	 center	 in	 a	 densely	 populated	
inner-	city	area	with	a	skew	in	the	population	towards	lower	socio-








prepaid	envelope	by	which	 to	 return	 the	completed	questionnaire	
pack,	and	a	complimentary	tea	bag.	Patients	with	TTR	<50%,	were	
also	identified	via	the	DAWN	database	and	invited	to	a	pharmacist-	
led	 consultation	 in	 clinic.	 For	 the	TTR	<50%	group,	 patients	were	










decisions. TTR was calculated by the Rosendaal method and was 


























TT₂R	 scores	 calculated.26-30	 As	 the	HAS-	BLED	 scoring	 system	 for	
determining	bleeding	risk	allocates	1	point	 for	TTR	<60%	which	 is	
also	the	grouping	variable,	true	HAS-	BLED	and	adjusted	HAS-	BLED	
scores	were	 calculated,	where	 the	 adjusted	HAS-	BLED	 score	 dis-
counts	the	point	allocated	for	TTR	<60%.
2.1 | Study tools
Illness	 beliefs,	 medication	 beliefs,	 and	 treatment	 satisfaction/
anticoagulation-	specific	quality	of	life	were	assessed	using	a	question-
naire	pack	comprised	of	the	Revised	Illness	Perceptions	Questionnaire	
(IPQ-	R),	 the	 Beliefs	 about	Medicines	Questionnaire	 (BMQ),	 and	 the	





The	 IPQ-	R	 and	 BMQ	 are	 derived	 from	 Leventhal’s	 Common	
Sense	Model	of	Health	and	Illness	(CSM)	which	explains	that	when	
confronted	with	health	threats,	coping	mechanisms	deconstruct	the	
threat	 into	various	 illness	representations:	 identity,	timeline	acute-	
chronic,	timeline	cyclical,	consequences,	personal	control,	treatment	
control,	 cause,	 illness	 control,	 and	 emotional	 distress.31	 The	BMQ	
assesses	 beliefs	 regarding	 medication	 on	 four	 subscales;	 general	
harm	 and	 general	 overuse	 explore	 beliefs	 surrounding	medication	
in	general.	Specific	necessity	determines	the	extent	the	patient	rec-
ognises	the	need	for	VKA	therapy,	while	the	specific	concern	sub-
scale	 determines	 how	 strong	 their	 anxieties	 towards	 VKAs	 are.32 
The	 ACTS	 measures	 anticoagulation-	specific	 QoL	 and	 treatment	
satisfaction	 on	 two	 subscales:	 benefits	 and	 burdens	 of	 anticoag-
ulation	 therapy.33,34	 For	 descriptions	 of	 all	 subscales	 see	 Table	1.	
The	 Cronbach’s	 alpha	 test	 for	 internal	 consistency	 was	 used	 on	
each	 of	 the	 questionnaire	 subscales	where	 an	 alpha	 score	 >0.6	 is	
considered reliable.35	 All	 subscales	 had	 Cronbach’s	 α	 scores	 >0.6	






NY).	Descriptive	 statistics	were	used	 to	describe	clinical	 and	demo-
graphic	 variables.	 Chi-	squared	 tests	 were	 used	 to	 compare	 nomi-
nal	 variables.	Continuous	variables	were	assessed	 for	normality	 and	
TABLE  1 Subscale	Description	and	Scoring
Questionnaire Subscale Description Minimum score Maximum score














Emotional	Response Emotional	response	evoked	by	illness 6 30




are overused in health care
4 20



























































This	 study	 was	 reviewed	 and	 approved	 by	 the	 London-	Dulwich	
Research	 Ethics	 Committee	 (13/LO/1468)	 and	 King’s	 College	





326	 (31%)	were	 returned	 and	 15	 of	 these	were	 incomplete	 and	
not	 used.	 The	 identity	 section	of	 IPQ-	R	was	 consistently	 poorly	
answered	 with	 many	 patients	 leaving	 several	 questions	 blank,	
therefore	this	section	of	the	IPQ-	R	was	not	analyzed.	Patients	in	







Amongst	AF	 patients,	 those	with	 TTR	 >75%	had	 stronger	 chronic	
timeline	beliefs	and	were	less	likely	to	believe	that	their	illness	was	
cyclical	(Table	3).	TTR	<50%	patients	had	greater	concern	about	the	

























showed	 significant	 differences	 between	 clusters	 in	 every	 subscale,	
validating	the	cluster	analysis,	see	Supplementary	Table	S2.
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TABLE  2 Clinical	and	Demographic	Information	of	Recruited	Patients













TTR	(median,	IQR) 90	(81-	100) 39	(33-	45) — 95	(87-	100) 38	(32-	44) — 97	(89-	100) 35	(34-	36)
KCHc	(n,	%) 86	(46) 66	(40) 0.278 41	(46) 23	(53) 0.424 19	(54) 3	(43)
Male	(n,	%) 112	(60) 105	(64) 0.427 53	(60) 24	(56) 0.693 26	(74) 4	(47)
Caucasian	(n,	%) 175	(94) 143	(90) 0.215 77	(87) 31	(72) 0.044 32	(91) 7	(100)





221	(129-	352) 116	(41-	275) <0.001 269	(127-	595) 139	(78-	260) <0.001 299	(154-	610) 194	(133-	198)
CHADS2  
(mean,	SD)d
2.22	(1.23) 2.15	(1.26) 0.601 N/A NA
CHA2DS2VASc	
(mean,	SD)e
3.61	(1.44) 3.37	(1.45) 0.130 N/A NA
HAS-	BLED	(mean,	
SD)f












0.27	(0.26) 0.21	(0.29) 0.057 0.47	(0.33) 0.60	(0.39) 0.066 0.43	(0.29) 0.28	(0.28)
Congestive	Heart	
Failure	(n,	%)
51	(30) 51	(31) 0.828 8	(9) 1	(2) 0.143 6	(22) 6	(86)
Hypertension	 
(n,	%)
106	(62) 99	(60) 0.709 40	(47) 14	(33) 0.130 13	(48) 2	(29)
Stroke	(n,	%) 38	(22) 36	(22) 0.930 1	(1) 2	(5) 0.215 7	(26) 5	(71)
Vascular	Disease	
(n,	%)
13	(8) 10	(6) 0.576 4	(5) 3	(7) 0.583 1	(4) 0	(0)
Type	II	Diabetes	
Mellitus	(n,	%)
28	(16) 41	(25) 0.054 14	(16) 6	(14) 0.731 6	(22) 1	(14)
Bleeding	History	
(n,	%)
21	(12) 20	(12) 0.965 7	(8) 3	(7) 0.816 5	(19) 1	(14)
Myocardial	
Infarction	(n,	%)
28	(16) 16	(10) 0.073 3	(3) 3	(7) 0.375 7	(26) 3	(43)
Ischaemic Heart 
Disease	(n,	%)
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3.3 | Factors influencing TTR
Variables	linked	with	low	TTR	according	to	univariate	logistic	regres-
sion with P ≤ .1	that	were	subsequently	entered	into	a	multivariate	






AF patients VTE patients
TTR >75% 
(n = 187) 
Mean (SD)
TTR <50% 
(n = 164) 
Mean (SD) Sig.
TTR >75% 
(n = 89) 
Mean (SD)
TTR <50% 




24.3	(3.8) 23.1	(4.1) 0.008 25.2	(4.3) 23.3	(5.0) 0.015
Timeline	Cyclical 8.9	(3.1) 10.4	(3.2) 0.001 8.0	(3.3) 10.3	(3.7) 0.002
Consequences 16.2	(3.9) 17.6	(4.4) 0.003 16.8	(4.1) 18.4	(4.5) 0.037
Personal	Control 18.8	(4.4) 19.7	(4.0) 0.089 18.4	(4.8) 19.8	(4.0) 0.141
Treatment	Control 16.4	(2.3) 16.9	(2.6) 0.074 17.1	(2.4) 17.1	(3.0) 0.898
Illness	Coherence 18.5	(3.9) 18.3	(3.9) 0.446 18.9	(4.0) 17.2	(4.4) 0.027
Emotional	Response 14.2	(4.4) 15.3	(4.7) 0.006 14.5	(5.4) 15.8	(5.1) 0.230
Psychological	Cause 13.4	(4.1) 13.4	(4.0) 0.533 11.4	(3.9) 13.0	(4.5) 0.067
Risk	Factor	Cause 17.0	(3.9) 17.8	(4.2) 0.067 15.3	(3.8) 16.5	(5.1) 0.255
Immune	Cause 6.4	(1.9) 6.8	(1.7) 0.017 6.0	(2.1) 6.9	(2.5) 0.041
Accidental	Cause 4.5	(1.5) 4.6	(1.5) 0.142 5.2	(1.7) 5.6	(1.8) 0.184
BMQ General Harm 19.9	(6.5) 23.5	(8.0) 0.044 8.9	(2.4) 9.7	(2.9) 0.141
General Overuse 11.4	(2.7) 10.1	(2.7) 0.075 11.2	(2.7) 11.8	(3.3) 0.281
Specific	Concern 12.0	(3.5) 13.9	(3.7) 0.001 13.0	(3.6) 14.6	(4.4) 0.032
Specific	Necessity 17.3	(3.7) 16.5	(3.2) 0.017 18.5	(3.6) 17.8	(3.8) 0.196
ACTS Burdens 19.9	(6.5) 23.5	(8.0) 0.001 23.5	(8.3) 26.3	(9.3) 0.093
Benefits 11.4	(2.7) 10.1	(2.7) 0.001 11.7	(2.9) 11.6	(2.4) 0.721
TABLE  4 Cluster	Characteristics
Cluster Description
Accepting of therapy and 
illness
Cautious of therapy not 
illness
Accepting of therapy but 
fearful of illness




Very	Chronic Chronic Very	Chronic Chronic
Timeline	Cyclical Stable Stable Stable Unsure
Consequences Mild Mild Mild Moderate
Personal	Control High High High High
Treatment	Control High Moderate Moderate Moderate
Illness	Coherence High Moderate High Moderate
Emotion Low Low Moderate Moderate
General Harm Low Low Low Low
General Overuse Low Moderate Moderate Moderate
Specific	Concern Low Moderate Moderate High
Specific	Necessity High Moderate High High
Burdens Very	Low Very	Low Low Moderate
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an	ACE-	inhibitor	or	drug	increasing	bleeding	risk,	no	thrombotic	his-
tory,	and	belief	cluster	1.	The	resulting	model	found	that	only	diag-
nosis	 and	belief	 cluster	were	 associated	with	TTR	<50%	 (Table	6).	
VTE	patients	were	more	 than	half	as	 likely	 to	have	poor	 INR	con-
trol	 (OR	=	0.49;	95%	CI	0.29,	0.77)	while	 there	was	 increasing	 risk	
moving	from	cluster	1	to	4	where	cluster	4	patients	were	over	four	
times	more	 likely	 to	be	poorly	controlled	 (OR	=	4.75;	95%	CI	2.75,	









greater	conviction	 in	 their	 illness	being	caused	by	accident	or	bad	
luck.	AF	patients	with	TTR	>75%	were	more	likely	to	attribute	their	






VKAs	 and	 were	 more	 likely	 to	 recognize	 the	 benefits	 of	 therapy	
than	AF	patients.	Although	compared	to	AF	patients,	VTE	patients	
reported	greater	burdens	of	VKA	therapy,	this	was	not	statistically	

























Age	(median,	IQR) 73	(66-	81) 77	(69-	84) 72	(62-	78) 70	(61-	77)
TTR	>75%	(n,	%) 132	(71.0) 47	(51.1) 64	(53.3) 28	(36.8)
Male	(n,	%) 121	(65.1) 60	(65.2) 78	(65.0) 37	(48.7)
Caucasian	(n,	%) 180	(96.8) 79	(87.8) 103	(86.6) 61	(81.3)
AF	(n,	%) 127	(68.3) 68	(73.9) 75	(62.5) 47	(61.8)
VTE	(n,	%) 43	(23.1) 21	(22.8) 34	(28.3) 22	(29.0)
Other	(n,	%) 16	(8.6) 3	(3.3) 11	(9.2) 7	(9.2)
CHADS2	(mean,	SD)
a 2.1	(1.2) 2.3	(1.4) 2.3	(1.4) 2.0	(1.0)
CHA2DS2VASc	(mean,	
SD)a
3.4	(1.3) 3.6	(1.6) 3.4	(1.6) 3.4	(1.2)
HAS-	BLED	(mean,	SD) 1.7	(1.0) 1.9	(0.9) 1.8	(0.9) 1.8	(0.9)
CCI	10	year	mortality	
(mean,	SD)
0.4	(0.3) 0.3	(0.3) 0.3	(0.3) 0.3	(0.3)







95% C.I. for OR
Lower Upper
AF	(Ref) 1.00 — —
 VTE 0.49 0.29 0.77
 Other 0.22 0.07 0.46
Cluster	1	(Ref) 1.00 — —
 Cluster	2 2.25 1.35 3.77
 Cluster	3 2.32 1.42 3.74
 Cluster	4 4.75 2.75 8.77
Diagnosis	of	AF	and	Cluster	1	were	baseline	comparators.
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4.1 | Understanding and knowledge of illness
Despite	all	patients	being	prescribed	VKAs	lifelong,	timeline	beliefs	
were	 markedly	 different	 between	 groups.	 Those	 with	 TTR	 >75%	
















interventions	 in	 anticoagulation	 that	 have	 targeted	 education	
alone	have	had	limited	success,38,39	there	is	scope	to	improve	TTR	
by	addressing	inaccurate	beliefs	if	combined	with	other	behavior	
change	 techniques.	 Interventions	 utilising	 nonmedical	 personnel	
such	as	pharmacists	and	nurses	have	proved	to	be	successful.40
4.2 | Subjective experiences of illness and treatment
AF	 patients	 with	 TTR	 <50%	 reported	 fewer	 benefits	 of	 antico-
agulation	 and	 greater	 emotional	 distress,	 specific	 concerns	 and	
burdens	of	therapy,	while	TTR	<50%	VTE	patients	scored	higher	
in	specific	concerns	and	trended	towards	greater	burdens.	This	is	
indicative	 of	 negative	 experiences	 regarding	 emotional	 wellbe-
ing	and	treatment	satisfaction.	This	is	consistent	with	Lane	et	al’s	
work	 which	 found	 that	 high	 baseline	 specific	 concern	was	 con-
sistent	with	worse	QoL.41	 It	 is	 likely	 that	 the	experience	of	out-	
of-	range	 INR	 results,	 dose	 changes,	 and	 more	 frequent	 testing	









VKA	 therapy	 was	 not	 associated	 with	 TTR	 category	 in	 regres-






TTR >75% TTR <50%
AF 
(n = 187) 
Mean (SD)
VTE 
(n = 89) 
Mean (SD) Sig.
AF 
(n = 164) 
Mean (SD)
VTE 




24.3	(3.8) 25.2	(4.3) 0.092 23.1	(4.1) 23.3	(5.0) 0.889
Timeline	Cyclical 8.9	(3.1) 8.0	(3.3) 0.200 10.4	(3.2) 10.3	(3.7) 0.724
Consequences 16.2	(3.9) 16.8	(4.1) 0.283 17.6	(4.4) 18.4	(4.5) 0.374
Personal	Control 18.8	(4.4) 18.4	(4.8) 0.595 19.7	(4.0) 19.8	(4.0) 0.927
Treatment	Control 16.4	(2.3) 17.1	(2.4) 0.075 16.9	(2.6) 17.1	(3.0) 0.915
Illness	Coherence 18.5	(3.9) 18.9	(4.0) 0.529 18.3	(3.9) 17.2	(4.4) 0.119
Emotional	Response 14.2	(4.4) 14.5	(5.4) 0.337 15.3	(4.7) 15.8	(5.1) 0.586
Psychological	Cause 13.4	(4.1) 11.4	(3.9) 0.001 13.4	(4.0) 13.0	(4.5) 0.245
Risk	Factor	Cause 17.0	(3.9) 15.3	(3.8) 0.001 17.8	(4.2) 16.5	(5.1) 0.051
Immune	Cause 6.4	(1.9) 6.0	(2.1) 0.135 6.8	(1.7) 6.9	(2.5) 0.999
Accidental	Cause 4.5	(1.5) 5.2	(1.7) 0.004 4.6	(1.5) 5.6	(1.8) 0.003
BMQ General Harm 19.9	(6.5) 8.9	(2.4) 0.097 23.5	(8.0) 9.7	(2.9) 0.074
General Overuse 11.4	(2.7) 11.2	(2.7) 0.478 10.1	(2.7) 11.8	(3.3) 0.500
Specific	Concern 12.0	(3.5) 13.0	(3.6) 0.020 13.9	(3.7) 14.6	(4.4) 0.340
Specific	Necessity 17.3	(3.7) 18.5	(3.6) 0.012 16.5	(3.2) 17.8	(3.8) 0.042
ACTS Burdens 19.9	(6.5) 23.5	(8.3) 0.001 23.5	(8.0) 26.3	(9.3) 0.069
Benefits 11.4	(2.7) 11.7	(2.9) 0.704 10.1	(2.7) 11.6	(2.4) 0.004
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4.3 | Belief patterns associated with TTR
Cluster	 analysis	 revealed	 four	 distinct	 patterns	 of	 beliefs	 among	
patients	 ranging	 from	cluster	1,	who	were	accepting	of	both	 their	
therapy	and	 illness,	 to	 those	who	were	 fearful	of	both,	 i.e,	 cluster	
4.	Regression	analysis	 found	patients	at	 the	highest	 risk	of	having	
poor	INR	control	were	those	with	AF	and	beliefs	akin	to	cluster	4.	
Although	cluster	4	was	made	up	of	disproportionately	more	women,	
gender	was	unrelated	 to	TTR	 in	 the	 regression	analysis	and	 is	not	
consistently related to adherence or TTR in the literature.22
VTE	patients	were	less	likely	to	have	low	TTR.	This	may	be	due	
to	previous	experience	of	thrombosis	where	VKAs	were	the	active	
treatment.	 Referring	 to	 the	 COM-	B	 model,	 motivation	 to	 adhere	
would	 be	 enhanced,	 while	 enhancing	 necessity	 perceptions.	 The	
TREAT	 study	 found	 that	 baseline	 specific	 necessity	 beliefs	 were	





without	 stroke,	 although	 the	 number	 of	 stroke	 patients	was	 rela-
tively	small.	Stroke	was	unrelated	to	TTR	in	the	regression	analysis.
The	 regression	 analysis	 has	been	 reported	unadjusted	 for	 age,	





strong	 evidence	 that	 any	 clinical	 demographic	 is	 associated	 with	
adherence	to	anticoagulation	or	TTR	that	would	provide	a	basis	by	
which	to	adjust	for	them,22,44 nor is there a theoretical basis to do so.
4.4 | Beliefs of AF and VTE patients
TTR	>75%	VTE	patients	had	a	greater	recognition	of	the	necessity	
for	VKA	 therapy	 compared	 to	 those	with	AF,	 similar	 to	 findings	
in	Dutch	patients.45	Unexpectedly,	our	VTE	patients	had	greater	
concerns	and	reported	more	burdens	related	to	VKAs.	The	NCDs	
between	AF	 and	VTE	patients	were	 similar	 in	 both	 groups.	 This	
is	 in	 contrast	 to	 previous	 research,	 which	 has	 found	 that	 VTE	
patients	 had	 higher	 differentials	 compared	 to	 AF	 patients.45	 A	












could	explain	 the	 raised	necessity	 and	consequence	perceptions	
in	VTE.














poses,	 clinical	 demographic	 variables	 such	 as	 age,	 gender,	 disease	
severity,	duration	of	warfarin	treatment,	comorbidities,	and	income	














however,	 some	 incomplete	 questionnaires	were	 submitted.	 In	 this	
case	patients	were	asked	to	be	complete	missing	answers	after	the	







and	 QoL	 in	 patients	 prescribed	 chronic	 VKA	 therapy	 are	 signifi-
cantly	associated	with	the	behavior	of	anticoagulated	patients	and	
are	 associated	with	 INR	 control.	 The	multiple	 disparities	 between	
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